CA3165514A1 - Composition and use of engineered anti-cd20 monoclonal antibodies refactory to tumor immune-suppressive factor ca125/muc16 - Google Patents

Composition and use of engineered anti-cd20 monoclonal antibodies refactory to tumor immune-suppressive factor ca125/muc16

Info

Publication number
CA3165514A1
CA3165514A1 CA3165514A CA3165514A CA3165514A1 CA 3165514 A1 CA3165514 A1 CA 3165514A1 CA 3165514 A CA3165514 A CA 3165514A CA 3165514 A CA3165514 A CA 3165514A CA 3165514 A1 CA3165514 A1 CA 3165514A1
Authority
CA
Canada
Prior art keywords
seq
antibody
residues
immuno
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3165514A
Other languages
English (en)
French (fr)
Inventor
Nicholas C. Nicolaides
Luigi Grasso
James Bradford Kline
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navrogen Inc
Original Assignee
Navrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navrogen Inc filed Critical Navrogen Inc
Publication of CA3165514A1 publication Critical patent/CA3165514A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
CA3165514A 2019-12-31 2020-12-29 Composition and use of engineered anti-cd20 monoclonal antibodies refactory to tumor immune-suppressive factor ca125/muc16 Pending CA3165514A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962955477P 2019-12-31 2019-12-31
US62/955,477 2019-12-31
PCT/US2020/067345 WO2021138346A1 (en) 2019-12-31 2020-12-29 Composition and use of engineered monoclonal antibodies refractory to tumor immuno-suppressive factors

Publications (1)

Publication Number Publication Date
CA3165514A1 true CA3165514A1 (en) 2021-07-08

Family

ID=76687271

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3165514A Pending CA3165514A1 (en) 2019-12-31 2020-12-29 Composition and use of engineered anti-cd20 monoclonal antibodies refactory to tumor immune-suppressive factor ca125/muc16

Country Status (11)

Country Link
US (1) US20230203182A1 (zh)
EP (1) EP4085075A4 (zh)
JP (1) JP7437511B2 (zh)
KR (1) KR20220144797A (zh)
CN (1) CN114901698A (zh)
AU (1) AU2020419050A1 (zh)
BR (1) BR112022012872A2 (zh)
CA (1) CA3165514A1 (zh)
IL (1) IL294257A (zh)
MX (1) MX2022008137A (zh)
WO (1) WO2021138346A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024040024A1 (en) * 2022-08-15 2024-02-22 Navrogen, Inc. Fc-ENGINEERED MONOCLONAL ANTIBODIES REFRACTORY TO TUMOR IMMUNOSUPPRESSIVE ICAM-1/CD54

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
ES2651170T3 (es) * 2010-09-21 2018-01-24 Altor Bioscience Corporation Moléculas de fusión solubles multímeras de IL-15 y métodos para elaborar y usar las mismas
WO2013109279A2 (en) * 2012-01-19 2013-07-25 Therapeutic Proteins Inc. Stabilization of the anti-cd20 antibody rituximab
US20140004037A1 (en) 2012-01-19 2014-01-02 Therapeutic Proteins, Inc. Stabilization of the anti-cd20 antibody rituximab
US20150141620A1 (en) * 2012-06-01 2015-05-21 Momenta Pharmaceuticals, Inc. Methods related to rituximab
CN105753986B (zh) 2016-04-24 2019-12-10 赵磊 一类抗cd20靶向抗体及用途

Also Published As

Publication number Publication date
MX2022008137A (es) 2022-10-03
CN114901698A (zh) 2022-08-12
AU2020419050A1 (en) 2022-08-25
JP7437511B2 (ja) 2024-02-22
IL294257A (en) 2022-08-01
EP4085075A4 (en) 2024-04-03
EP4085075A1 (en) 2022-11-09
KR20220144797A (ko) 2022-10-27
US20230203182A1 (en) 2023-06-29
JP2023508706A (ja) 2023-03-03
BR112022012872A2 (pt) 2022-09-06
WO2021138346A1 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
CN111630068B (zh) 抗cd47抗体及其用途
CN108368170B (zh) 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
CN107849133B (zh) 抗cd166抗体、可活化抗cd166抗体及其使用方法
BR112021005585A2 (pt) proteínas de ligação a sirpa e métodos de uso das mesmas
CN116410316A (zh) 抗cd47抗体及其用途
CA2955947A1 (en) Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
CA2978942A1 (en) Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
CA2918795A1 (en) Multispecific antibodies, multispecific activatable antibodies and methods of using the same
KR20160127825A (ko) 항-mcam 항체 및 관련된 사용 방법
KR102197478B1 (ko) 식도암을 검출 및 치료하기 위한 조성물 및 방법
JP2022505925A (ja) 抗ｔｉｍ－３抗体
AU2021250840A1 (en) Compositions and methods for detecting and treating ovarian cancer
JP2017529832A (ja) Ｆｃγ受容体ＩＩＢおよびＦｃε受容体に対する新規の抗体
KR20180105642A (ko) 위암의 검출 및 치료를 위한 조성물 및 방법
US20210285960A1 (en) Composition and Methods for Measuring Antibody Dynamics
US20160039931A1 (en) Hybridoma Clones and Monoclonal Antibodies to Tetraspanin 8
CN117098548A (zh) 抗b7-h3抗体及其用途
US20230203182A1 (en) Composition and Use of Engineered Monoclonal Antibodies Refractory to Tumor Immuno-Suppressive Factors
US9862773B2 (en) Hybridoma clones and monoclonal antibodies to CD9
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
US20210040174A1 (en) Composition and Use of Humoral Immune Suppressor Antagonists for the Treatment of Humoral Immune Suppressed Diseases
WO2024067864A1 (en) Anti-lair1 antibodies and their uses
WO2024040024A1 (en) Fc-ENGINEERED MONOCLONAL ANTIBODIES REFRACTORY TO TUMOR IMMUNOSUPPRESSIVE ICAM-1/CD54
CN118284623A (zh) 抗cd161抗体及其用途
WO2023070201A1 (en) Claudin 18.2-binding antibodies and fragments thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220620

EEER Examination request

Effective date: 20220620

EEER Examination request

Effective date: 20220620

EEER Examination request

Effective date: 20220620

EEER Examination request

Effective date: 20220620

EEER Examination request

Effective date: 20220620

EEER Examination request

Effective date: 20220620